- The incidence of rheumatic immune-related adverse events (IRAEs) resulting from treatment with immune checkpoint inhibitors (ICI) remains unclear, but significant.
Why this matters
- Physicians should be aware of the potential for rheumatoid side effects of ICI treatment.
- Prevalence, clinical characteristics, and treatment data were extracted and summarized from studies that reported musculoskeletal and rheumatic IRAEs with ICI treatment.
- Funding: Not indicated.
- 52 studies with original data on ICI treatment and information about musculoskeletal or rheumatic IRAEs were selected, including 33 clinical trials, 3 observational studies, and 16 series or case reports.
- Among clinical trials, arthralgia was reported in 24 trials and incidence ranged from 1% to 43%, myalgia was reported in 12 and ranged from 2% to 21%, arthritis reported in 5 and ranged from 1% to 7%, and a case of giant cell vasculitis reported in 1 trial and unspecified vasculitis in another trial.
- Among observational and case studies, there were reports of vasculitis, myositis, inflammatory arthritis, and lupus nephritis.
- Inconsistent classification and limited data on IRAEs.